Disclosure: I am a prior $FMI shareholder but have no current long or short position in the stock.
In trading today, Foundation Medicine $FMI stock has completed a remarkable roundtrip, giving up all the gains from a spectacular move from sub-$20 to over $50 on the back of their splashy deal with Roche announced at the JP Morgan Healthcare Conference. While the stock has been dribbling downward for months, the last ten bucks comes as a result of their second quarter earnings release and conference call held on July 29, 2015 where the company slashed its 2015 guidance for FoundationOne test numbers and revenue.
In trading today, Foundation Medicine $FMI stock has completed a remarkable roundtrip, giving up all the gains from a spectacular move from sub-$20 to over $50 on the back of their splashy deal with Roche announced at the JP Morgan Healthcare Conference. While the stock has been dribbling downward for months, the last ten bucks comes as a result of their second quarter earnings release and conference call held on July 29, 2015 where the company slashed its 2015 guidance for FoundationOne test numbers and revenue.
RSS Feed
